Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

J. Sanz, M. Labopin, G. Choi, A. Kulagin, J. Peccatori, J. Vydra, P. Reményi, J. Versluis, M. Rovira, D. Blaise, H. Labussière-Wallet, J. Montoro, S. Sica, E. Meijer, M. Itälä-Remes, N. Schaap, CE. Bulabois, S. Piemontese, M. Mohty, F. Ciceri

. 2024 ; 143 (24) : 2534-2543. [pub] 20240613

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013516

There is a paucity of information on how to select the most appropriate unrelated donor (UD) in hematopoietic stem cell transplantation (HSCT) using posttransplant cyclophosphamide (PTCy). We retrospectively analyzed the characteristics of 10/10 matched UDs (MUDs) and 9/10 mismatched UDs (MMUDs) that may affect transplant outcomes in patients with acute myeloid leukemia (AML) in first or second complete remission (CR1 or CR2). The primary end point was leukemia-free survival (LFS). Overall, 1011 patients were included with a median age of 54 years (range, 18-77). Donors had a median age of 29 years (range, 18-64); 304 (30%) were females, of which 150 (15% of the whole group) were donors to male recipients, and 621 (61%) were MUDs; 522 (52%) had negative cytomegalovirus (CMV-neg) serostatus, of which 189 (19%) were used for CMV-neg recipients. Donor age older than 30 years had a negative impact on relapse (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.06-1.8), LFS (HR, 1.4; 95% CI, 1.12-1.74), overall survival (HR 1.45; 95% CI, 1.14-1.85) and graft-versus-host disease (GVHD) free, relapse-free survival (HR, 1.29; 95% CI, 1.07-1.56). In addition, CMV-neg donors for CMV-neg recipients were associated with improved LFS (HR, 0.74; 95% CI, 0.55-0.99). The use of MMUD and female donors for male recipients did not significantly impact any transplant outcomes. For patients undergoing HSCT from a UD with PTCy for AML, donor age <30 years significantly improves survival. In this context, donor age might be prioritized over HLA match considerations. In addition, CMV-neg donors are preferable for CMV-neg recipients. However, further research is needed to validate and refine these recommendations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013516
003      
CZ-PrNML
005      
20240905133324.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2023023697 $2 doi
035    __
$a (PubMed)38657278
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sanz, Jaime $u Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Department de Medicina de la Universitat de València; CIBERONC, Instituto Carlos III, Madrid, Spain $1 https://orcid.org/0000000169344619
245    10
$a Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT / $c J. Sanz, M. Labopin, G. Choi, A. Kulagin, J. Peccatori, J. Vydra, P. Reményi, J. Versluis, M. Rovira, D. Blaise, H. Labussière-Wallet, J. Montoro, S. Sica, E. Meijer, M. Itälä-Remes, N. Schaap, CE. Bulabois, S. Piemontese, M. Mohty, F. Ciceri
520    9_
$a There is a paucity of information on how to select the most appropriate unrelated donor (UD) in hematopoietic stem cell transplantation (HSCT) using posttransplant cyclophosphamide (PTCy). We retrospectively analyzed the characteristics of 10/10 matched UDs (MUDs) and 9/10 mismatched UDs (MMUDs) that may affect transplant outcomes in patients with acute myeloid leukemia (AML) in first or second complete remission (CR1 or CR2). The primary end point was leukemia-free survival (LFS). Overall, 1011 patients were included with a median age of 54 years (range, 18-77). Donors had a median age of 29 years (range, 18-64); 304 (30%) were females, of which 150 (15% of the whole group) were donors to male recipients, and 621 (61%) were MUDs; 522 (52%) had negative cytomegalovirus (CMV-neg) serostatus, of which 189 (19%) were used for CMV-neg recipients. Donor age older than 30 years had a negative impact on relapse (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.06-1.8), LFS (HR, 1.4; 95% CI, 1.12-1.74), overall survival (HR 1.45; 95% CI, 1.14-1.85) and graft-versus-host disease (GVHD) free, relapse-free survival (HR, 1.29; 95% CI, 1.07-1.56). In addition, CMV-neg donors for CMV-neg recipients were associated with improved LFS (HR, 0.74; 95% CI, 0.55-0.99). The use of MMUD and female donors for male recipients did not significantly impact any transplant outcomes. For patients undergoing HSCT from a UD with PTCy for AML, donor age <30 years significantly improves survival. In this context, donor age might be prioritized over HLA match considerations. In addition, CMV-neg donors are preferable for CMV-neg recipients. However, further research is needed to validate and refine these recommendations.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    12
$a nepříbuzný dárce $7 D061349
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a senioři $7 D000368
650    _2
$a mladiství $7 D000293
650    12
$a akutní myeloidní leukemie $x terapie $x mortalita $7 D015470
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mladý dospělý $7 D055815
650    _2
$a testování histokompatibility $7 D006650
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a věkové faktory $7 D000367
650    _2
$a nemoc štěpu proti hostiteli $x etiologie $7 D006086
650    _2
$a HLA antigeny $x imunologie $7 D006680
650    _2
$a přežití bez známek nemoci $7 D018572
655    _2
$a časopisecké články $7 D016428
700    1_
$a Labopin, Myriam $u EBMT Paris Office, Hospital Saint-Antoine, Paris, France
700    1_
$a Choi, Goda $u University Medical Center Groningen, Groningen, The Netherlands
700    1_
$a Kulagin, Alexander $u Raisa Memorial Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia $1 https://orcid.org/0000000295894136
700    1_
$a Peccatori, Jacopo $u Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Italy $1 https://orcid.org/0000000346391716
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion-Prague, Prague, Czech Republic $1 https://orcid.org/0000000242743895
700    1_
$a Reményi, Péter $u Dél-pesti Centrumkórház, Budapest, Hungary $1 https://orcid.org/0009000696649067
700    1_
$a Versluis, Jurjen $u Erasmus MC Cancer Institute, Rotterdam, The Netherlands
700    1_
$a Rovira, Montserrat $u BMT Unit, Department of Haematology, Institute of Haematology and Oncology, IDIBAPS, Hospital Clinic, Josep Carreras Leukaemia Research Foundation, University of Barcelona, Barcelona, Spain
700    1_
$a Blaise, Didier $u Programme de Transplantation & Therapie Cellulaire-Marseille, Marseille, France $1 https://orcid.org/0000000256849447
700    1_
$a Labussière-Wallet, Hélène $u Centre Hospitalier Lyon Sud, Lyon, France
700    1_
$a Montoro, Juan $u Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Department de Medicina de la Universitat de València; CIBERONC, Instituto Carlos III, Madrid, Spain $1 https://orcid.org/0000000300248068
700    1_
$a Sica, Simona $u Universita Cattolica del Sacro Cuore, Rome, Italy
700    1_
$a Meijer, Ellen $u VU University Medical Center, Amsterdam, The Netherlands
700    1_
$a Itälä-Remes, Maija $u Turku University Hospital, Turku, Finland $1 https://orcid.org/0000000158441632
700    1_
$a Schaap, Nicolaas $u Radboud University Medical Center, Nijmegen, The Netherlands
700    1_
$a Bulabois, Claude Eric $u CHU Grenoble Alpes-Université Grenoble Alpes, Grenoble, France
700    1_
$a Piemontese, Simona $u Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Italy
700    1_
$a Mohty, Mohamad $u Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris, France
700    1_
$a Ciceri, Fabio $u Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Italy $u Vita-Salute San Raffaele University, Milan, Italy
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 143, č. 24 (2024), s. 2534-2543
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38657278 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133318 $b ABA008
999    __
$a ok $b bmc $g 2143371 $s 1225382
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 143 $c 24 $d 2534-2543 $e 20240613 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace